Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication made on May 16, 2025 wherein Financial Results for the quarter and year ended March 2025 were published.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences published audited financial results for the quarter and year ended March 31, 2025 in Business Standard and Pratahkal newspapers on May 16, 2025, as required under SEBI listing rules. For FY25, the company reported total income from operations of Rs. 1,283.76 crores (vs Rs. 1,288.92 cr in FY24) and a net profit of Rs. 0.54 crores, a major turnaround from a Rs. 566.96 cr loss in the previous year. Q4 FY25 revenue came in at Rs. 273.01 crores (vs Rs. 299.43 cr in Q4 FY24) with a net loss of Rs. 2.10 crores, sharply improved from the Rs. 255.45 cr loss in Q4 FY24. FY25 EPS stood at Rs. 0.14 per share. The Board had earlier granted in-principle approval on January 24, 2025 for the proposed demerger of the CRAMS and Polymers business into an independent listed entity. The company also completed a Rs. 449.95 cr rights issue in June 2024, with proceeds used to repay borrowings.
The sharp swing from massive losses to a marginal profit signals operational recovery, but profitability remains thin and revenue is flat, so sentiment impact is likely muted. The proposed CRAMS and Polymers demerger is a key catalyst to watch for potential value unlocking for shareholders.